Outcome of Immunotherapy in Adrenocortical Carcinoma - A retrospective cohort study.
Hanna RemdeL Schmidt-PenningtonM ReuterLaura-Sophie LandwehrM JensenH LahnerOtilia KimpelB AltieriK LaubnerJ SchreinerJ BojungaS KircherC A KunzeA PohrtM V TeleanuD HübschmannA StenzingerH GlimmS FröhlingFassnacht MartinKnut MaiM KroissPublished in: European journal of endocrinology (2023)
In the real-life setting we observe a response comparable to other second-line therapies and an acceptable safety profile in ACC patients receiving different ICI. The relevance of PD-L1 as a marker of response and the potentially more favourable outcome in nivolumab treated patients require confirmation.